AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
AstraZeneca (NYSE: AZN) and Cellworks today announced a collaboration supported by the Wellcome Trust to speed the design of novel combination therapies for the treatment of drug-sensitive and resistant tuberculosis. This collaboration will also pave the way for the creation of platforms and approaches to handle Multi Drug Resistant Tuberculosis (MDR-TB), a condition that is reaching epidemic proportions in many developing parts of the world.
Current therapies for tuberculosis (TB) are based on creating combinations of three to four drugs and cycling through ad-hoc regimens, which are largely ineffective against MDR-TB. Together, Cellworks and AstraZeneca will pull from a pool of existing anti-infective drugs and attempt to find an effective combination with better efficacy and lower toxicity than the treatment regimens provided today.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.